NextCure

About NextCure

NextCure, Inc. is a clinical-stage biopharmaceutical entity operating within the immuno-oncology sector. The company was incorporated in 2015, establishing its headquarters in Beltsville, Maryland. Its co-founders include Michael Richman and Lieping Chen, M.D., Ph.D., who brought extensive experience to the venture. Richman had previously served as President and CEO of Amplimmune, which was acquired by AstraZeneca, while Dr. Chen is a distinguished immunologist from Yale University known for his work in T-cell co-stimulation and co-inhibition. This background in immunology and biopharmaceutical leadership forms the foundation of NextCure's strategic direction.

The company's core business revolves around the discovery and development of first-in-class immunomedicines designed to treat cancer and other immune-related diseases. NextCure's operational strategy centers on its proprietary FIND-IO (Functional, Integrated, NextCure Discovery in Immuno-Oncology) platform. This technology enables the company to analyze immune cells and their interactions to identify novel molecular targets, moving beyond the more common approach of targeting single cell types. The goal is to develop therapies that restore normal immune function, particularly for patients who have not responded to existing treatments or have experienced disease progression. The business model is typical for a clinical-stage biopharmaceutical firm, where value is created through the progression of its drug candidates through the rigorous phases of clinical trials, with revenue generation likely dependent on future partnerships, licensing agreements, or the eventual commercialization of approved therapies. Its primary client base consists of patients with cancer types that are not adequately addressed by current therapeutic options.

The company went public in May 2019, raising approximately $96.8 million through its initial public offering on the Nasdaq Global Select Market under the ticker symbol “NXTC”. NextCure's pipeline includes several drug candidates, with NC260 and NC410 being key assets in its clinical development programs. NC410 is a fusion protein designed to target LAIR-1, an immunomodulatory receptor, aiming to promote an anti-tumor immune response. NC260 is a monoclonal antibody targeting the B7-H4 protein, which is overexpressed in various cancers and contributes to an immunosuppressive tumor microenvironment.